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been shown by antibody characterization in patients, antigen-
speci®c serum adsorption studies, genetics, animal models of both
passive and active induction of disease, and speci®c cleavage of
desmoglein 1 by a protease (Stanley et al, 2001). As in all diseases,
there may be alternative pathophysiologic mechanisms in some
cases, but at this point there is no convincing evidence for
antiacetylcholine receptor antibodies as a cause of pemphigus. In
short, we stand by our previous editorial (Stanley et al, 2001).
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Possible Role for Non-Desmoglein Antigen in Pemphigus
To the Editor:
The editorial ``Pemphigus: is there another half of the story?'', by
Stanley et al (2001), signals a healthy controversy regarding the
pathogenesis of pemphigus vulgaris. Despite the solid evidence that
antidesmoglein (Dsg) antibodies have the central role in pemphigus
vulgaris (PV) and foliaceous (PF), recent data raise questions that
need to be addressed (Kalish, 2000). Data supporting a role for non-
Dsg autoantigens in pemphigus include the following (Nguyen et
al, 2000):
(1) PV sera devoid of anti-Dsg1 activity produce blisters in
Dsg3(±/±) mice. Dsg3(±/±) mice develop few spontaneous
erosions, but with injection of this PV sera develop massive bullae,
similar to those in Dsg3(+/+) mice. This con®rms the importance
of inactivating Dsg3 to produce PV-like blisters, but also indicates
that anti-Dsg are not the sole pathogenic antibodies in PV sera.
(2) PV sera immunoprecipitates multiple non-Dsg antigens from
both normal and Dsg3 (±/±) keratinocytes, including a antigen (not
Dsg3) that migrates at 130 kDa.
(3) Absorption of PV sera with Dsg3-Ig fusion protein removes
pathogenicity; however, antibodies eluted from this column react
with multiple antigens from both Dsg3(±/±) and normal keratino-
cytes. This was clearly demonstrated with western blots using
eluted antibodies.
The only discrepancy between the data of Nguyen et al (2000)
and that of John Stanley (Mahoney et al, 1999) relates to the site of
blister formation in desmoglein (±/±) mice that receive PF sera.
The solution is to repeat these experiments with shared reagents.
This discrepancy is not critical to the overall interpretation of the
data, as Nguyen demonstrates, by several different sensitive assays,
that the PV sera used lacks anti-Dsg1 activity.
The above data suggest that PV is mediated by additional
autoantibodies acting in concert with anti-Dsg. It is theorized that
antibodies to keratinocyte cholinergic receptors may be the missing
component (Nguyen et al, 2000). This last point is not proven, but
is based on data, and should not be lightly dismissed. I have very
high regard for all the investigators involved, and eagerly await
additional scienti®c developments.
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Expression of Basal-Cell Adhesion Molecule (B-CAM) is
Associated with Immature States of Human Keratinocytes
To the Editor:
We thank Dr. Boehncke for his interest and comments
regarding our work. Unfortunately, his group's publication
(Bernemann et al, 2000) was not yet available to us at the time
our manuscript was prepared and submitted. While we found
B-CAM reactivity preferentially within the basal epidermal layer
in in¯ammatory disorders or epithelial skin tumors (SchoÈn et al,
2000), Dr. Boehncke proposed B-CAM as a marker for
terminal differentiation of human keratinocytes based upon
suprabasal antibody binding in a subset of normal human skin
biopsies (Bernemann et al, 2000). Another study reports ``weak
and variable'' B-CAM expression in the upper layers of the
epidermis without specifying number or origin of the specimens
tested (Garin-Chesa et al, 1994). The same study reports
polarized basal expression of B-CAM in other strati®ed
epithelia, such as esophagus or uterine cervix. The latter and
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